ProCE Banner Activity

Barriers to Accessing Dermatologists and Rheumatologists for Patients With Psoriasis and Psoriatic Arthritis: Impact and Solutions

Clinical Thought
Expert faculty discuss the impact of reduced access to dermatologists and rheumatologists on patients with PsO and PsA and potential solutions, such as telehealth.

Released: August 20, 2021

Expiration: August 19, 2022

Share

Faculty

April W. Armstrong

April W. Armstrong, MD, MPH

Professor and Chief of Dermatology
University of California Los Angeles
Los Angeles, California

Philip Mease

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

April W. Armstrong, MD, MPH

Professor and Chief of Dermatology
University of California Los Angeles
Los Angeles, California

April W. Armstrong, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Aslan, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavent, Dermira, EPI Health, Incyte, Janssen, Leo, Lilly, Novartis, Ortho, Parexel, Pfizer, Regeneron, Sanofi, Sun, and UCB and funds for research support from Bristol-Myers Squibb, Dermavent, Dermira, Lilly, Leo, Pfizer, and UCB.

Philip Mease, MD, MACR

Director, Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, Washington

Philip Mease, MD, MACR, has disclosed that he has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; funds for research from AbbVie, Amgen, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and fees for non-CME/CE services from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB.